Longevity Fund es un fondo de inversión dedicado a surtir de dinero a compañías biotecnológicas centradas principalmente en mejorar nuestra longevidad y combatir los procesos de envejecimiento. De su página web:
“We’re looking to invest in 3 things:
- Companies testing the hypothesis that aging can be modified by single things – specific targets, small molecules or biologics. We think there’s enough cross-species evidence of oddly broad-acting genetic pathways that it is worth testing this hypothesis in humans.
- Companies developing novel technologies for manipulating biological systems. We’re fans of the idea that living things, or things made by them, can treat life (antibodies, cellular therapy, things that manipulate the immune system or electroceuticals). We’re very open to anything in this regard.
- Things which don’t fall into either bucket above, or combine the two. We try to be non-dogmatic, so if you can make a good case for it, we’ll take a look.”
En TechCrunch entrevistan brevemente a la promotora de Longevity Fund, Laura Deming, que cuenta tan sólo con 23 años. Os recomiendo echarle un vistazo a lo que dice.
“[…]not long ago, if you talked with most VCs about aging, they didn’t think there was anything there. I think aging is such a young science, they hadn’t heard about it. Meanwhile, I care a lot about it, and though we don’t know if it’ll work or not, it’s not unlike [biotech companies trying to tackle] cancer in that way, and if you believe in cancer companies, you should also care about aging companies.”
“Earlier, our biggest challenge was getting other investors on board and convincing them that aging has become a place to play. Now that’s a non-issue, which is great. Our job is to help the companies get other investors on board, so it’s wonderful to see excitement in the space begin to build.”
De momento, estas son las empresas a las que están apoyando: